Scientists are meeting to develop a better prognostic tool for breast cancer progression in early stages. Today and tomorrow, the recently created consortium of the HYPOSENS project gathers in LEITAT offices in Barcelona for the kick-off meeting of the project. HYPOSENS is a H2020-funded project that aims to develop a widely accepted, non-invasive and crucial prognostic tool for breast cancer progression in early stages to help clinicians and specially oncologists.
As coordinator, LEITAT hosted the meeting and took care of the organisation. During the meeting, partners will have the occasion to meet physically after many months of preparation and start with the execution of this great project. Each work package will be discussed in detail to assure that objectives will be reached.
The HypoSens imaging system is strategically designed to offer a non-invasive alternative to the Sentinel Lymph Node Biopsy, the current surgical procedure for breast cancer staging. With an approximate cost of 60,000€ per device unit and additional 5,000€ per patient, the device is an affordable, accurate, easy to use prognostic solution for clinicians towards more accurate and fast diagnostics and personalised treatment options.The initial target of the project is metastatic breast cancer, with potential later involvement in other cancer markets, e.g. vulval, renal, colorectal, gastric etc (via the use of different tumor-targeting moiety).
With an estimated 1.7 million new cases each year, breast cancer is the most common cancer among women worldwide. Its low cost will enable a wide and fast take-up by clinicians and hospitals leading to an important reduction of the economic and societal burden related to the diagnosis and treatment of cancer.